What’s the deal? Massive Bio, a precision oncology and AI-enabled real-world data company, has made a strategic investment in Rivvi, an agentic AI infrastructure startup for healthcare and life sciences. Announced August 4, 2026 at the Ai4 conference in Las Vegas, it is Massive Bio’s first strategic investment in another AI company. Financial terms were not disclosed.
What’s the endgame? The two companies plan to connect clinical intelligence, personalized patient outreach, and human-led navigation across oncology trials, patient support, care-gap closure, and medication adherence. The deal builds on their existing work across oncology trial programs.
Why now? An estimated 3% to 5% of US adults with cancer enroll in therapeutic clinical trials — a gap driven by fragmented data, complex eligibility criteria, limited workforce capacity, and narrow clinical windows to reach patients.
Massive Bio handles the intelligence layer, structuring clinical and biomarker data to identify relevant trials. Rivvi adds the action layer: AI agents that turn each match into an auditable workflow, reaching patients, surfacing barriers, coordinating next steps, and escalating to human teams.
Massive Bio’s multi-agent matching system was evaluated in 3,804 patients during routine operations. The peer-reviewed study reported more than 17,000 oncologist-confirmed matches, an F1 score of 0.82, and trial matching four times faster than conventional workflows. Rivvi has powered more than two million patient interactions across more than 500,000 patients, serving health systems, payers, pharmacies, PBMs, and life sciences organizations.
What did they say? “Rivvi is our inaugural AI investment because its conversational infrastructure compounds the value of our clinical intelligence,” said Selin Kurnaz, co-founder and chief executive officer of Massive Bio. She called it “disciplined capital deployment around a shared mission.”
“An eligible patient cannot benefit from an opportunity they never hear about, and in oncology the window can close quickly,” said Arturo Loaiza-Bonilla, co-founder and chief medical AI officer. “Clinical judgment stays with clinicians and choice stays with patients; AI creates the capacity to bring more people into an informed discussion.”
The signal: The move marks a deliberate expansion of Massive Bio’s strategy — building core AI products while deploying capital into complementary technologies that extend its platform. It establishes a model for how the company plans to accelerate the technologies surrounding it.
Read more: Massive Bio
Image credit: lydia_shiningbrightly
